We’re delighted to announce that Epilepsy Meds, the mobile-first clinical support app developed by Genetic Digital in partnership with Desitin Pharma and ChangeMed, has been awarded Silver at the 2025 PM Society Digital Awards.
The app was recognised in the HCP Education, Training & Support category for its innovation, impact, and collaborative development approach.
Born out of insights from multidisciplinary NHS advisory boards, Epilepsy Meds is designed to help healthcare professionals quickly filter and compare licensed anti-seizure medications based on key criteria such as formulation, excipients, and patient suitability — particularly for vulnerable groups like children and patients with dysphagia.
It provides ABPI-compliant access to SPCs and trusted prescribing data, all in one place — helping clinicians make faster, safer, and more confident prescribing decisions. Now in use across NHS Trusts, the app has also been endorsed by Young Epilepsy, Epilepsy Society, and Epilepsy Action, highlighting its value as a trusted tool for real-world clinical use.
“We’re incredibly proud of this award, and even more proud of the collaboration behind it,” said Damon Lightley, Managing Director at Genetic Digital. “This is a great example of what can be achieved when pharma, clinicians, and digital specialists work together with a shared goal of improving patient care.”
A huge congratulations to our clients at Desitin and ChangeMed, and thank you to the PM Society for recognising the work.